PMID- 31158747
OWN - NLM
STAT- Publisher
LR  - 20190606
IS  - 1768-3254 (Electronic)
IS  - 0223-5234 (Linking)
VI  - 177
DP  - 2019 May 17
TI  - C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the
      identification of potent, cell penetrant Jumonji C domain containing histone
      lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in
      cell-based target engagement assays.
PG  - 316-337
LID - S0223-5234(19)30451-9 [pii]
LID - 10.1016/j.ejmech.2019.05.041 [doi]
AB  - Residues in the histone substrate binding sites that differ between the KDM4 and 
      KDM5 subfamilies were identified. Subsequently, a C8-substituted
      pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to rationally exploit these 
      residue differences between the histone substrate binding sites in order to
      improve affinity for the KDM4-subfamily over KDM5-subfamily enzymes. In
      particular, residues E169 and V313 (KDM4A numbering) were targeted. Additionally,
      conformational restriction of the flexible pyridopyrimidinone C8-substituent was 
      investigated. These approaches yielded potent and cell-penetrant dual
      KDM4/5-subfamily inhibitors including 19a (KDM4A and KDM5B Ki=0.004 and 0.007muM,
      respectively). Compound cellular profiling in two orthogonal target engagement
      assays revealed a significant reduction from biochemical to cell-based activity
      across multiple analogues; this decrease was shown to be consistent with 2OG
      competition, and suggests that sub-nanomolar biochemical potency will be required
      with C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one compounds to achieve
      sub-micromolar target inhibition in cells.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Masson SAS.. All rights
      reserved.
FAU - Le Bihan, Yann-Vai
AU  - Le Bihan YV
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Lanigan, Rachel M
AU  - Lanigan RM
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Atrash, Butrus
AU  - Atrash B
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - McLaughlin, Mark G
AU  - McLaughlin MG
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Velupillai, Srikannathasan
AU  - Velupillai S
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK.
FAU - Malcolm, Andrew G
AU  - Malcolm AG
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - England, Katherine S
AU  - England KS
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department
      of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK.
FAU - Ruda, Gian Filippo
AU  - Ruda GF
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK.
FAU - Mok, N Yi
AU  - Mok NY
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Tumber, Anthony
AU  - Tumber A
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department
      of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK.
FAU - Tomlin, Kathy
AU  - Tomlin K
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Saville, Harry
AU  - Saville H
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Shehu, Erald
AU  - Shehu E
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - McAndrew, Craig
AU  - McAndrew C
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Carmichael, LeAnne
AU  - Carmichael L
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Bennett, James M
AU  - Bennett JM
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department
      of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK.
FAU - Jeganathan, Fiona
AU  - Jeganathan F
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Eve, Paul
AU  - Eve P
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Donovan, Adam
AU  - Donovan A
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Hayes, Angela
AU  - Hayes A
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Wood, Francesca
AU  - Wood F
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Raynaud, Florence I
AU  - Raynaud FI
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Fedorov, Oleg
AU  - Fedorov O
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department
      of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK.
FAU - Brennan, Paul E
AU  - Brennan PE
AD  - Structural Genomics Consortium (SGC), University of Oxford, ORCRB Roosevelt
      Drive, Oxford, OX3 7DQ, UK; Target Discovery Institute (TDI), Nuffield Department
      of Medicine, University of Oxford, NDMRB, Roosevelt Drive, Oxford, OX3 7FZ, UK.
FAU - Burke, Rosemary
AU  - Burke R
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - van Montfort, Rob L M
AU  - van Montfort RLM
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Rossanese, Olivia W
AU  - Rossanese OW
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK.
FAU - Blagg, Julian
AU  - Blagg J
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK. Electronic address: julian.blagg@icr.ac.uk.
FAU - Bavetsias, Vassilios
AU  - Bavetsias V
AD  - Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research,
      London, UK. Electronic address: vassilios.bavetsias@icr.ac.uk.
LA  - eng
PT  - Journal Article
DEP - 20190517
PL  - France
TA  - Eur J Med Chem
JT  - European journal of medicinal chemistry
JID - 0420510
OTO - NOTNLM
OT  - Histone demethylases
OT  - KDM inhibitors
OT  - KDM4 subfamily
OT  - KDM5 subfamily
OT  - Pyridopyrimidinones
EDAT- 2019/06/04 06:00
MHDA- 2019/06/04 06:00
CRDT- 2019/06/04 06:00
PHST- 2019/01/04 00:00 [received]
PHST- 2019/05/14 00:00 [revised]
PHST- 2019/05/14 00:00 [accepted]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2019/06/04 06:00 [medline]
PHST- 2019/06/04 06:00 [entrez]
AID - S0223-5234(19)30451-9 [pii]
AID - 10.1016/j.ejmech.2019.05.041 [doi]
PST - aheadofprint
SO  - Eur J Med Chem. 2019 May 17;177:316-337. doi: 10.1016/j.ejmech.2019.05.041.